Metastastic castration-resistant prostate cancer: predictors of long-term response to Abiraterone


Researchers aimed to identify clinical predictors of long-term response to Abiraterone [ Zytiga ] ( defined as more than 12 months drug exposure ) in a retrospective cohort of metastatic castration-resistant prostate cancer patients treated in post-Docetaxel setting at 24 Italian centers.

A total of 143 patients met the inclusion criteria. Their median age was 73 years, median Gleason score 8 and median Abiraterone exposure 20 months.

At the univariate analysis, a significant correlation with the duration of Abiraterone exposure was found for Gleason score ( hazard ratio, HR=0.82, 95% CI 0.71-0.96; p=0.012 ), PSA ( HR=1.10, 95% CI 1.03-1.18; p=0.08 ) and lactic dehydrogenase levels ( HR=1.22, 95% CI 1.02-1.46; p=0.027 ), while the association between lower alkaline phosphatase levels and treatment duration was marginally significant ( HR=1.07, 95% CI 0.99-1.16; p=0.074 ).

Only PSA and Gleason score were predictive of long-term treatment duration in the multivariate analysis. No other clinical factors resulted to be predictive of sustained response to Abiraterone, including metastatic disease at diagnosis and visceral disease, suggesting that all subgroups of patients may derive a substantial clinical benefit from Abiraterone treatment.

These findings need to be validated in prospective, larger studies. ( Xagena )

Verzoni E et al, Oncotarget 2016; Epub ahead of print

XagenaMedicine_2016



Indietro

Altri articoli

Lynparza ( Olaparib ) has been approved in the European Union ( EU ) for patients with metastatic castration-resistant prostate...


Cabozantinib ( Cabometyx ) may enhance response to immune checkpoint inhibitors ( ICIs ) by promoting an immune-permissive microenvironment and...


SPARTAN has evaluated Apalutamide ( Erleada ) versus placebo in patients with nonmetastatic castration-resistant prostate cancer ( nmCRPC ) and...


Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic...


Data, presented at 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting, showed clinical improvement in median radiologic...


ADXS-PSA, an attenuated Listeria monocytogenes-based immunotherapy that targets prostate-specific antigen ( PSA ), is designed to generate antigen-specific T cell...


Researchers have evaluated the use of Abiraterone acetate ( Zytiga ) ( 1,000 mg ) plus Prednisone ( 5 mg...


Data from the pivotal phase 3 LATITUDE clinical trial showed Abiraterone acetate ( Zytiga ) plus Prednisone, in combination with...


STAMPEDE is a multigroup, multistage platform trial protocol investigating the efficacy of additional therapy at the time of inception of...


Over the past decade, several systemic agents as Docetaxel, Cabazitaxel, Sipuleucel-T, Abiraterone and Enzalutamide have improved overall survival ( OS...